BiVACOR's Total Artificial Heart Receives FDA Breakthrough Device Designation
BiVACOR, a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
The designation supports the BiVACOR TAH as a bridge to transplant (BTT) for adults with severe biventricular or univentricular heart failure where current treatments, including LVADs, are not viable. The FDA's Breakthrough Device program is reserved for technologies that may significantly improve outcomes for patients with life-threatening or irreversibly debilitating conditions. It offers priority regulatory interaction and accelerated pathways to approval.
'This is more than a regulatory milestone. It's a validation of a concept we've spent decades proving that a fully implantable, total artificial heart isn't just possible, it's necessary,' said Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR. 'Patients with biventricular failure have been overlooked for too long. The early results from our clinical trial show that we can give them a second chance, without the compromises of older technologies. The Breakthrough Device Designation puts us on a faster track to deliver exactly that.'
The milestone follows the first phase of BiVACOR's FDA Early Feasibility Study, where five patients in the U.S. received the TAH between July and November 2024. Based on positive safety and performance data, the FDA approved the expansion of the trial to include 15 additional patients starting later this year.
BiVACOR's device represents a new category in artificial heart technology. Compact enough to fit most men and women, the TAH uses magnetic levitation, similar to maglev trains, to suspend a single dual-sided rotor. This rotor simultaneously powers the right and left circulatory systems, mimicking the natural heartbeat without valves or mechanical wear points. Its simplified design allows for pulsatile flow, large blood gaps to reduce trauma, and long-term durability.
'We've seen every kind of artificial heart technology over the last four decades, but this is the first system I've encountered that combines engineering elegance, efficiency, and safety with true clinical viability,' said William Cohn, MD, BiVACOR Chief Medical Officer and heart surgeon at the Texas Heart Institute. 'The early results are remarkable with no strokes, no device-related complications, and a safety profile unlike anything in this space. With Breakthrough status in hand, we're entering the next phase with the wind at our backs and real momentum to bring this to more patients.'
Heart failure affects more than 6 million Americans, and thousands of patients each year progress to irreversible biventricular failure. However, the number of available donor hearts remains stagnant, with fewer than 4,500 transplants performed annually in the U.S. BiVACOR is targeting this critical gap with a durable artificial replacement engineered for eventual long-term support.
The BiVACOR TAH is currently investigational and not approved for commercial use.
About BiVACOR
BiVACOR® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at www.bivacor.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250529170802/en/
CONTACT: Media Contact:
Dana Summers
Penman PR
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: CARDIOLOGY BIOTECHNOLOGY FDA HEALTH GENERAL HEALTH HEALTH TECHNOLOGY OTHER SCIENCE MEDICAL DEVICES RESEARCH SCIENCE CLINICAL TRIALS
SOURCE: BiVACOR
Copyright Business Wire 2025.
PUB: 05/30/2025 11:40 AM/DISC: 05/30/2025 11:38 AM
http://www.businesswire.com/news/home/20250529170802/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
New blood pressure guidelines recommend skipping alcohol, earlier treatment
The American Heart Association and the American College of Cardiology issued their first new set of guidelines to help minimize hypertension since 2017. The new guidelines used by clinicians nationwide recommend that Americans limit the amount of alcohol they consume. While forgoing alcohol consumption altogether is preferable, the groups found that men should limit their intake to no more than two drinks per day, while women should limit their intake to no more than one per day. Systolic and diastolic blood pressure both increase over time with alcohol intake, according to a report published Aug. 14. The data found that those who avoid drinking alcohol have the lowest risk of hypertension, and that those who reduce their intake by at least 50% experienced healthy blood pressure levels. The updated guidelines are now instructing doctors to recommend treatment to those with stage 1 hypertension rather than just stage 2. More: Can alcohol cause cancer? Here's what the science says While the 2017 guidelines would prescribe lifestyle changes and medication to those with a systolic blood pressure level of 140 mm Hg or higher, clinicians are now advised to recommend lifestyle changes to those in the 130–139 mm Hg range. The blood pressure gauge uses a unit of measurement called millimeters of mercury (mm Hg) to measure the pressure in your blood vessels. "By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure and reduce the toll of heart disease, kidney disease, Type 2 diabetes and dementia," Chair of the guideline writing committee Dr. Daniel Jones said in a news release. Guidelines still urge people to reduce salt intake Experts continue to emphasize that lowering sodium intake is essential for minimizing hypertension. According to health guidelines, it's recommended that individuals limit their sodium consumption to 2,300 mg per day, with an ideal target of 1,500 mg per day. The report emphasizes that most adults get their sodium intake from eating packaged and restaurant foods, rather than adding salt to the food they prepare. The new guidelines encourage people to examine the sodium content in the food they eat and use potassium-enriched salt substitutes when possible. The guidelines recommend that people adopt a heart-healthy diet, such as the DASH eating plan, which prioritizes meals high in vegetables, fruits, whole grains, legumes, nuts, seeds, and low-fat or nonfat dairy products, while also including lean meats and poultry, fish, and non-tropical oils. Exercise is also recommended, with experts urging at least 75-150 minutes of physical activity every week, from cardio to weight training. Is heart disease still the leading cause of death? Yes, heart disease continues to be the leading cause of death in the United States and worldwide despite there being many ways to avoid hypertension and maintain a healthy blood pressure, according to the report. Nearly half (46.7%) of adults in the U.S. have higher-than-normal blood pressure, referring to either stage 1 or stage 2 hypertension. Stage 1 hypertension refers to those with a systolic blood pressure of 130 to 139 mm Hg or a diastolic blood pressure between 80 and 89 mm Hg. Meanwhile, stage 2 hypertension refers to those with a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher. More: Millions of us eat soy sauce regularly. Is it bad for you? What factors shape blood pressure? The new guidelines list the various factors that influence one's blood pressure, including the following: Behavioral, environmental, hormonal and genetic influences. Diet quality Dietary factors including sodium intake (lower is recommended), potassium intake (higher is recommended), and alcohol consumption (little to none is recommended) Intake of fiber, calcium, magnesium and plant protein Weight and related metabolic issues Age, obesity and insulin resistance Sleep disturbances and psychosocial stressors Physical activity and fitness Environmental exposures and chemical toxins, including air pollution and heavy metals This article originally appeared on USA TODAY: New blood pressure guidelines suggest you skip alcohol, more Solve the daily Crossword
Yahoo
27 minutes ago
- Yahoo
Why UnitedHealth Stock Was Climbing on Wednesday
Key Points The insurer maintained its dividend policy. This was obviously a relief to worried investors. 10 stocks we like better than UnitedHealth Group › UnitedHealth (NYSE: UNH) stock was proving to be beneficial for investors' financial health on Hump Day. They were trading the big health insurance company's stock up by nearly 4% in late-session action, in no small part because of a fresh dividend declaration. That performance marked it as an outlier, as the S&P 500 index had only ticked up by 0.2% at that stage. Quarterly payout incoming Before market open, UnitedHealth's board of directors authorized the payment of a quarterly dividend of $2.21 per each of the company's common shares. This is to be dispensed on Sept. 23 to investors of record as of Sept. 15. Despite some challenges to its business recently, UnitedHealth has held steadfastly to its dividend policy. It switched from an annual to a quarterly disbursement in 2010, and has raised it on a regular basis since then. Over that stretch of time, it has risen strongly from $0.03 to the present level. Although Wednesday's dividend declaration was in character for UnitedHealth, the investor reaction might have been something of a relief rally. Earlier this year the company absorbed a big group of Medicare Advantage patients and to its surprise, those folks made more visits to doctors and other healthcare professionals than anticipated. This impacted fundamentals, and some investors were surely worried the dividend would be suspended. The high profile of a high yield Although it's unwise to buy a stock purely to clock the dividend, UnitedHealth's payout is notable for being generous. Unlike other dividend-paying healthcare stocks, this one has quite a high yield -- nearly 3.3%, against the 1.2% average of all S&P 500 index component stocks. It's little wonder investors were happy the company is maintaining its payout. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. Why UnitedHealth Stock Was Climbing on Wednesday was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
California Coastal Commission opposes SpaceX launch expansion on West Coast, again
By Steve Gorman LOS ANGELES (Reuters) -The California Coastal Commission voted on Thursday against a plan by Elon Musk's SpaceX to nearly double the number of Falcon 9 rocket launches the company is permitted to conduct each year from Vandenberg Space Force Base, from 50 to 95. But as was the case when the commission voted last October to oppose a previous SpaceX launch expansion from 36 to 50 at the installation, the U.S. government can merely override the objections of California regulators and approve the latest plan. The U.S. Department of the Air Force, parent agency of the Space Force, has taken the position that the proposed launch expansion at Vandenberg, about 60 miles (97 km) northwest of Santa Barbara on the central California coast, is a federal activity exempt from further state oversight. A commission staff report countered that of 51 rockets launched last year from Vandenberg, SpaceX Falcon 9s accounted for 46 of them. While SpaceX flies some missions for the Defense Department and NASA, the enlarged launch operations SpaceX envisions are primarily for carrying payloads for the company's own Starlink satellite network, the report said. SpaceX also has sought to expand its launch facilities at NASA's Kennedy Space Center in Cape Canaveral, Florida. Air Force officials did not attend Thursday's commission meeting in Calabasas, north of Los Angeles, where the panel voted 11-0 against SpaceX. Neither representatives for SpaceX nor the Air Force could immediately be reached for comment. SpaceX has sued the California Coastal Commission over its previous objections, accusing the agency of singling out Musk's company for greater regulation in retaliation for his political views. In addition to allowing as many as 95 launches a year by the company's workhorse Falcon 9, the new plan would permit up to five Falcon Heavy rocket launches annually, and up to 24 landings by the company's reusable rocket boosters, twice as many as previously approved. Two new landing zones at the base would also be built. At-sea landings would also be increased. In recommending disapproval, commission staff cited what it called insufficient information about the plan and concerns over noise pollution and wildlife disturbance from more frequent, louder sonic booms as SpaceX launch activity escalates. The staff report also cited the need for more frequent closures of public beaches and campgrounds that lie within the launch hazard zones around the base. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
